| Title |
Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis
|
|---|---|
| Published in |
Rheumatology International, May 2013
|
| DOI | 10.1007/s00296-013-2772-6 |
| Pubmed ID | |
| Authors |
Marina Amaral de Ávila Machado, Mariana Michel Barbosa, Alessandra Maciel Almeida, Vânia Eloisa de Araújo, Adriana Maria Kakehasi, Eli Iola Gurgel Andrade, Mariangela Leal Cherchiglia, Francisco de Assis Acurcio |
| Abstract |
Biological agents directed against tumor necrosis factor (TNF) represent therapeutic options for patients with ankylosing spondylitis with high disease activity despite use of non-steroidal anti-inflammatory drugs. To evaluate the efficacy and safety of the anti-TNF agents infliximab, etanercept, adalimumab, golimumab, and certolizumab for the treatment of ankylosing spondylitis, we performed a systematic review of randomized clinical trials on adult patients with ankylosing spondylitis using articles culled from the EMBASE, MEDLINE, Cochrane Controlled Trials Register and LILACS databases (September/2012), manual literature search, and the gray literature. Study selections and data collection were performed by two independent reviewers, with disagreements solved by a third reviewer. The following outcomes were evaluated: ASAS 20 response, disease activity, physical function, vertebral mobility, adverse events, and withdraws. The meta-analysis was performed using the Review Manager(®) 5.1 software by applying the random effects model. Eighteen studies were included in this review. No study of certolizumab was included. Patients treated with anti-TNF agents were more likely to display an ASAS 20 response after 12/14 weeks (RR 2.21; 95 % CI 1.91; 2.56) and 24 weeks (RR 2.68; 95 % CI 2.06; 3.48) compared with controls, which was also true for several other efficacy outcomes. Meta-analysis of safety outcomes and withdraws did not indicate statistically significant differences between treatment and control groups after 12 or 30 weeks. Adalimumab, infliximab, etanercept, and golimumab can effectively reduce the signs and symptoms of the axial component of ankylosing spondylitis. Safety outcomes deserve further study, especially with respect to long-term follow-ups. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Venezuela, Bolivarian Republic of | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 101 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 2 | 2% |
| Unknown | 99 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 14 | 14% |
| Researcher | 12 | 12% |
| Student > Ph. D. Student | 11 | 11% |
| Student > Bachelor | 11 | 11% |
| Student > Postgraduate | 10 | 10% |
| Other | 24 | 24% |
| Unknown | 19 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 45 | 45% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 9% |
| Nursing and Health Professions | 4 | 4% |
| Engineering | 3 | 3% |
| Economics, Econometrics and Finance | 2 | 2% |
| Other | 13 | 13% |
| Unknown | 25 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 May 2013.
All research outputs
#18,339,860
of 22,711,242 outputs
Outputs from Rheumatology International
#1,786
of 2,174 outputs
Outputs of similar age
#147,697
of 196,556 outputs
Outputs of similar age from Rheumatology International
#24
of 38 outputs
Altmetric has tracked 22,711,242 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,174 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one is in the 9th percentile – i.e., 9% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 196,556 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 38 others from the same source and published within six weeks on either side of this one. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.